SCHEMBL23908262

SCHEMBL23908262

N#Cc1ccc(C(=O)NC2(c3ccc(-c4ccc(C(=O)O)nc4)cc3)CCC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 9/20 0.50
DEGS1 O15121 1/20 0.45
NAAA Q02083 1/20 0.43
CXCR3 P49682 1/20 0.43
MAP4K4 O95819 3/20 0.42
MINK1 Q8N4C8 2/20 0.41
TNIK Q9UKE5 2/20 0.41
VNN1 O95497 1/20 0.40
AKT1 P31749 1/20 0.38
FLT1 P17948 1/20 0.38
EGLN3 Q9H6Z9 1/20 0.38
AR P10275 1/20 0.38
ROCK2 O75116 1/20 0.38
ROCK1 Q13464 1/20 0.38
CSNK2A2 P19784 1/20 0.38
CSNK2A1 P68400 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22439054 0.88 DEGS1 (0.46) EGLN1DEGS1NAAACXCR3MAP4K4
SCHEMBL22439074 0.85 CXCR3 (0.43) EGLN1DEGS1NAAACXCR3MAP4K4
SCHEMBL22438582 0.85 CXCR3 (0.43) EGLN1DEGS1CXCR3MAP4K4MINK1
SCHEMBL22438623 0.85 IDO1 (0.48) EGLN1DEGS1NAAACXCR3MAP4K4
SCHEMBL22439019 0.85 DEGS1 (0.43) EGLN1DEGS1NAAACXCR3MAP4K4
SCHEMBL22438845 0.84 CXCR3 (0.42) EGLN1DEGS1NAAACXCR3MAP4K4
SCHEMBL23908250 0.84 MAP4K4 (0.46) EGLN1DEGS1NAAACXCR3MAP4K4
SCHEMBL22439043 0.84 EGLN1 (0.44) EGLN1DEGS1NAAACXCR3MAP4K4
SCHEMBL22439083 0.83 DEGS1 (0.43) EGLN1DEGS1NAAACXCR3MAP4K4
SCHEMBL22439274 0.83 MAP4K4 (0.43) EGLN1DEGS1NAAACXCR3MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3709986-B1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-11-01 EP claimed
US-11498904-B2 Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors MERCK SHARP & DOHME LLC (US) 2022-11-15 US claimed
US-20210317091-A1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-10-14 US claimed
EP-3709986-B1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-11-01 EP disclosed
EP-3709986-B1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-11-01 EP disclosed
US-11498904-B2 Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors MERCK SHARP & DOHME LLC (US) 2022-11-15 US disclosed
US-20210317091-A1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-10-14 US disclosed
US-20210317091-A1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317091-A1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS IDO1, IDO2, KYNU EGLN1 2299/4885DEGS1 4257/4885NAAA 802/4885
US-11498904-B2 Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors IDO1, IDO2, INMT EGLN1 2741/4885DEGS1 4569/4885NAAA 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.